{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:27:16Z","timestamp":1787239636385,"version":"build-2736575974"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Treatment targeting CD19 by a chimeric antigen receptor expressed on T cells (anti-CD19 CAR-T) has led to a breakthrough in the management and treatment of relapsed and refractory B- cell acute lymphoblastic leukemia (B-ALL). After infusion, the efficacy of anti-CD19 CAR-T is monitored by bone marrow negative minimal residual disease and the absence of peripheral CD19\n                    <jats:sup>+<\/jats:sup>\n                    B lymphocytes (B-cell aplasia). In patients who have received an allogenic Hematopoietic Stem Cell Transplantation (HSCT) prior to treatment with anti-CD19 CAR-T, monitoring lineage-specific chimerism could be helpful. We found that on 4 patients who received anti-CD19 CAR-T cells after HSCT and achieved early complete response, CD19\n                    <jats:sup>+<\/jats:sup>\n                    lineage mixed chimerism but not CD3\n                    <jats:sup>+<\/jats:sup>\n                    lineage mixed chimerism monitored by molecular techniques anticipated earlier than B-cell aplasia determined by flow cytometry, lack of effectiveness of anti-CD19 CAR-T and leukemia relapse. Donor lymphocyte infusions (DLIs) did not prevent relapse but recovered CD3\n                    <jats:sup>+<\/jats:sup>\n                    full donor chimerism. We suggest that continuous lineage chimerism analysis should be done routinely in patients who receive anti-CD19 CAR-T cells after HSCT and achieve complete remission because it can support early treatment intervention. However, the role of DLI in this setting is unclear, so further prospective studies should be developed.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.960412","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T02:28:37Z","timestamp":1659925717000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation"],"prefix":"10.3389","volume":"13","author":[{"given":"Isabel","family":"Mart\u00ednez-Romera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Gal\u00e1n-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Gonz\u00e1lez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Guerra Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonsoles","family":"San Rom\u00e1n Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Corral S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmina","family":"Mozo del Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bueno S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Sisinni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Gonz\u00e1lez Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serafin","family":"Castellano D\u00e1maso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"S\u00e1nchez Zapardiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Ruz Caracuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Balas P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2001.v7.pm11669214","article-title":"Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 tandem meetings of the international bone marrow transplant registry and the American society of blood an","volume":"7","author":"Antin","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/sj.bmt.1700721","article-title":"Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: The impact of quantitative PCR analysis for prediction of relapse and graft rejection in children","volume":"19","author":"Bader","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701119","article-title":"Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT","volume":"21","author":"Bader","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13945","article-title":"Repeated CD45RA-depleted DLI successfully increases donor chimerism in a patient with beta-thalassemia major after haploidentical stem cell transplant","volume":"25","author":"Chan","year":"2021","journal-title":"Pediatr Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184664","article-title":"Car-t after stem cell transplantation in b-cell lymphoproliferative disorders: Are they really autologous or allogenic cell therapies","volume":"13","author":"Bartol\u00f3-Ibars","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.135137","article-title":"Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia","volume":"101","author":"Preuner","year":"2016","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402017","article-title":"Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation","volume":"15","author":"Lion","year":"2001","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.198","article-title":"Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy","volume":"22","author":"Bader","year":"2004","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136187","article-title":"Pseudo-allogeneic CAR-T therapy after allogeneic stem cell transplantation in Relapsed\/Refractory b-cell NHL","volume":"136","author":"Siglin","year":"2020","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JCM.01420-19","article-title":"False-positive results for human immunodeficiency virus type 1 nucleic acid amplification testing in chimeric antigen receptor T cell therapy","volume":"58","author":"Hauser","year":"2019","journal-title":"J Clin Microbiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.05.016","article-title":"False-positive HIV nucleic acid amplification testing during CAR T-cell therapy","volume":"88","author":"Ariza-Heredia","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-822940","article-title":"False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy","volume":"131","author":"Laetsch","year":"2018","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17121","article-title":"Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed\/refractory large b-cell lymphoma","volume":"192","author":"Lutfi","year":"2021","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.708","article-title":"Cells to prevent\/treat relapse following allogeneic stem cell transplantation","volume":"2017","author":"Dietz","year":"2017","journal-title":"Hematology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.960412\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T02:28:38Z","timestamp":1659925718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.960412\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2022.960412"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.960412","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"article-number":"960412"}}